- Home
- INBX vs CABA Comparison
INBX vs CABA Comparison
Compare INBX & CABA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INBX
- CABA
- Stock Information
- Founded
- INBX 2010
- CABA 2017
- Country
- INBX United States
- CABA United States
- Employees
- INBX N/A
- CABA N/A
- Industry
- INBX Biotechnology: Pharmaceutical Preparations
- CABA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- INBX Health Care
- CABA Health Care
- Exchange
- INBX Nasdaq
- CABA Nasdaq
- Market Cap
- INBX 218.9M
- CABA 210.0M
- IPO Year
- INBX 2020
- CABA 2019
- Fundamental
- Price
- INBX $13.92
- CABA $2.45
- Analyst Decision
- INBX Hold
- CABA Strong Buy
- Analyst Count
- INBX 1
- CABA 9
- Target Price
- INBX N/A
- CABA $27.22
- AVG Volume (30 Days)
- INBX 81.4K
- CABA 4.7M
- Earning Date
- INBX 11-14-2024
- CABA 11-14-2024
- Dividend Yield
- INBX N/A
- CABA N/A
- EPS Growth
- INBX N/A
- CABA N/A
- EPS
- INBX 119.38
- CABA N/A
- Revenue
- INBX $1,568,000.00
- CABA N/A
- Revenue This Year
- INBX N/A
- CABA N/A
- Revenue Next Year
- INBX N/A
- CABA N/A
- P/E Ratio
- INBX $0.12
- CABA N/A
- Revenue Growth
- INBX 19.24
- CABA N/A
- 52 Week Low
- INBX $10.80
- CABA $1.76
- 52 Week High
- INBX $18.95
- CABA $26.35
- Technical
- Relative Strength Index (RSI)
- INBX 38.33
- CABA 36.81
- Support Level
- INBX $14.53
- CABA $2.76
- Resistance Level
- INBX $15.24
- CABA $2.80
- Average True Range (ATR)
- INBX 0.72
- CABA 0.42
- MACD
- INBX -0.10
- CABA -0.05
- Stochastic Oscillator
- INBX 19.16
- CABA 4.26
About INBX Inhibrx Inc.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.
About CABA Cabaletta Bio Inc.
Cabaletta Bio Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies, and exploring their potential to provide a deep and durable, perhaps curative, treatment, for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes Chimeric AutoAntibody Receptor, or CAART cells that are designed to selectively bind and eliminate only specific B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. Its CABA platform encompasses two strategies CARTA (chimeric antigen receptor T cells for autoimmunity) and CAART (chimeric autoantibody T cells) has the potential to be applied across a broad range of autoimmune diseases.